In a significant development and in a bid to have enough and improved vaccines to counter the Wuhan virus, the Drug Controller General of India (DCGI) has approved the study on mixing of two Covid-19 vaccines – Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin as recommended by the Subject Expert Committee (SEC) of the DCGI on 29 July granting approval to the study.
The expert committee is granting permission to CMC, Vellore in Tamil Nadu for conducting the Phase-4 clinical trial on 300 healthy volunteers for mixing of Covid-19 vaccines Covaxin and Covishield, reports India Today.
The study will determine if a person can be given two different vaccine shots to complete the vaccination course.
Also, the SEC had in July gave its approval to Bharat Biotech to conduct a trial that will involve combining the doses of Covaxin and Hyderabad-based firm’s other nasal COVID-19 vaccine.
Bharat Biotech is presently conducting trials of its intranasal COVID-19 vaccine in the country and the SEC has given its approval to conduct the phase 2 and 3 clinical trials, administering a dose each of Covaxin and the adenoviral intranasal vaccine with an interval between the two jabs.
Click here to subscribe to The Commune on Telegram and get the best stories of the day delivered to you personally.